AU2009218115B2 — Fibrosis inhibitor
Assigned to Nippon Shinyaku Co Ltd · Expires 2013-05-30 · 13y expired
What this patent protects
A fibrosis inhibitor is mainly provided. The fibrosis inhibitor contains either a heterocyclic derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient. In formula (1), R
USPTO Abstract
A fibrosis inhibitor is mainly provided. The fibrosis inhibitor contains either a heterocyclic derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient. In formula (1), R
Drugs covered by this patent
- Uptravi (SELEXIPAG) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.